These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34399555)

  • 21. Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study.
    Litchman T; Roy B; Kumar A; Sharma A; Njike V; Nowak RJ
    J Neurol Sci; 2020 Apr; 411():116690. PubMed ID: 32028072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term Efficacy of Non-steroid Immunosuppressive Agents in Anti-Muscle-Specific Kinase Positive Myasthenia Gravis Patients: A Prospective Study.
    Tan Y; Shi J; Huang Y; Li K; Yan J; Zhu L; Guan Y; Cui L
    Front Neurol; 2022; 13():877895. PubMed ID: 35775051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study.
    Dos Santos A; Noury JB; Genestet S; Nadaj-Pakleza A; Cassereau J; Baron C; Videt D; Michel L; Pereon Y; Wiertlewski S; Magot A
    Eur J Neurol; 2020 Nov; 27(11):2277-2285. PubMed ID: 32526053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myasthenia gravis with muscle-specific tyrosine kinase antibodies: A narrative review.
    Morren J; Li Y
    Muscle Nerve; 2018 Sep; 58(3):344-358. PubMed ID: 29461627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcome of generalized myasthenia gravis in Hong Kong Chinese.
    Lee CY; Lam CL; Pang SY; Lau KK; Teo KC; Chang RS; Chan KH
    J Neuroimmunol; 2015 Dec; 289():177-81. PubMed ID: 26616888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Seronegative myasthenia and myasthenia gravis with anti-MuSK antibody: a retrospective study of 20 cases].
    Aubert S; Salort-Campana E; Franques J; Uzenot D; Pouget J
    Rev Neurol (Paris); 2009 Nov; 165(11):901-10. PubMed ID: 19327804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody.
    Zhou Y; Yan C; Gu X; Zhou L; Lu J; Zhu W; Huan X; Luo S; Zhong H; Lin J; Lu J; Zhao C; Xi J
    Muscle Nerve; 2021 Jun; 63(6):824-830. PubMed ID: 33745138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antibodies in myasthenia gravis].
    Eymard B
    Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics Of acetylcholine-receptor-antibody-negative myasthenia gravis in a South African cohort.
    Huda S; Woodhall MR; Vincent A; Heckmann JM
    Muscle Nerve; 2016 Dec; 54(6):1023-1029. PubMed ID: 27105303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different characteristic phenotypes according to antibody in myasthenia gravis.
    Oh SJ; Morgan MB; Lu L; Hatanaka Y; Hemmi S; Young A; Claussen GC
    J Clin Neuromuscul Dis; 2012 Dec; 14(2):57-65. PubMed ID: 23172384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience.
    Pasnoor M; Wolfe GI; Nations S; Trivedi J; Barohn RJ; Herbelin L; McVey A; Dimachkie M; Kissel J; Walsh R; Amato A; Mozaffar T; Hungs M; Chui L; Goldstein J; Novella S; Burns T; Phillips L; Claussen G; Young A; Bertorini T; Oh S
    Muscle Nerve; 2010 Mar; 41(3):370-4. PubMed ID: 19882635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical and paraclinical profile of autoimmune myasthenia gravis in Ouagadougou, Burkina Faso].
    Lompo DL; Éric Some N; Ouedraogo AM; Yonli RP; Diallo O; Napon C; Millogo A; Kabore J
    Med Trop Sante Int; 2021 Dec; 1(4):. PubMed ID: 35685858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical significance of anti-heat shock cognate protein 71 antibody in myasthenia gravis.
    Munakata S; Chen M; Aosai F; Kawaguchi N; Nemoto Y; Norose K; Hattori T; Yano A
    J Clin Neurosci; 2008 Feb; 15(2):158-65. PubMed ID: 17981040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and scientific aspects of muscle-specific tyrosine kinase-related myasthenia gravis.
    Reddel SW; Morsch M; Phillips WD
    Curr Opin Neurol; 2014 Oct; 27(5):558-65. PubMed ID: 25159928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A case of anti-MuSK positive MG with recurrent right-sided heart failure as the initial manifestation].
    Matsumoto Y; Shima K; Yamaguchi K; Shimizu A
    Rinsho Shinkeigaku; 2020 Nov; 60(11):791-794. PubMed ID: 33115997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis.
    Roda RH; Doherty L; Corse AM
    Neuromuscul Disord; 2019 Jul; 29(7):554-561. PubMed ID: 31296355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.
    Vincent A; Leite MI
    Curr Opin Neurol; 2005 Oct; 18(5):519-25. PubMed ID: 16155434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AChRAb and MuSKAb double-seropositive myasthenia gravis: a distinct subtype?
    Zhang J; Chen Y; Chen J; Huang X; Wang H; Li Y; Liu W; Feng H
    Neurol Sci; 2021 Mar; 42(3):863-869. PubMed ID: 33438140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-MuSK myasthenia gravis presenting with purely ocular findings.
    Caress JB; Hunt CH; Batish SD
    Arch Neurol; 2005 Jun; 62(6):1002-3. PubMed ID: 15956173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.
    Farrugia ME; Robson MD; Clover L; Anslow P; Newsom-Davis J; Kennett R; Hilton-Jones D; Matthews PM; Vincent A
    Brain; 2006 Jun; 129(Pt 6):1481-92. PubMed ID: 16672291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.